Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The acidic transactivation-domain-bearing (TA) isoforms of p63 and p73 structurally and functionally resemble p53, whereas the ΔN isoforms (lacking the acidic transactivation domain) of p63 and p73 are frequently overexpressed in cancer and act primarily in a dominant-negative fashion against p53, TAp63 and TAp73 to inhibit their tumour-suppressive functions.
|
25409149 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
p63 and p73 in human cancer: defining the network.
|
17334395 |
2007 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we review these findings in the context of patient data and recent advances on molecular aspects of p73 function and discuss the implications for p73 as a target for cancer therapy.
|
18583938 |
2008 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, our results suggest that p73 compensates for loss of p53 and that targeting Mdm2 in p53-deficient cancers has therapeutic potential.<i>Cancer Res; 77(14); 3823-33.©2017 AACR</i>.
|
28576884 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that the functional impairment of p73 could be involved in the development of thyroid malignancies, defining p73 as a potential therapeutic target for thyroid cancer.
|
14522906 |
2003 |
Malignant Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Accordingly, although TP73 aberrant methylation was more frequent in meningiomas with 1p deletion (P<0.05), no association with the grade of malignancy could be established.
|
14734228 |
2004 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor protein p73 (TP73) has been reported to be dysregulated in various types of human cancer and associated with clinical progression and outcome.
|
31332036 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, possibilities for new therapeutic applications with p73 for cancer cell control are discussed.
|
10972855 |
2000 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Contribution of p53, p63, and p73 to the developmental diseases and cancer.
|
18348649 |
2008 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, despite a remarkable structural and partly functional similarity among p53, p63, and p73, mouse knockout studies revealed an unexpected functional diversity among them. p63 and p73 knockouts exhibit severe developmental abnormalities but no increased cancer susceptibility, whereas this picture is reversed for p53 knockouts.
|
15280445 |
2004 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
p63, p73 and p53 compose a family of transcription factors involved in cell response to stress and development. p53 is the most frequently mutated gene in cancer (50%) and loss of p53 activity is considered to be ubiquitous to all cancers.
|
16601753 |
2006 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To investigate the differences in mRNA and protein expressions of MDM2 (mouse double minute 2 homolog) and P73 in cancer and cancer-adjacent tissues in patients with non-small-cell lung carcinoma (NSCLC).
|
29452959 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We argue that the role of members of the p53 family as tumor suppressor proteins, their impact on the control of cellular ploidy, and their newly emerging connection with mitotic checkpoint regulatory genes support the suggestion that p73 and p53 could be two of the missing links among chromosomal instability, the mitotic checkpoint and cancer.
|
18406616 |
2008 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since their initial identification p53 homologues p63 and p73 have been expected to play a role in cancer development due to their close homology to p53, notoriously one of the most mutated genes in cancer.
|
21515338 |
2011 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.
|
25510918 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this article is to review the various contributions that the budding yeast has made to the understanding of p53, p63 and p73 biology and to envision new possible directions for yeast-based assays in the field of cancer as well as other p53-family-related diseases.
|
28915717 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, accumulating evidence suggest that p73 gene and its target genes are hypermethylated in the cancer of lymphoid origin.
|
17407586 |
2007 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Isoform-specific, real-time polymerase chain reaction and immunohistochemistry analysis on matched cancer and corresponding normal tissues from surgically resected non-small cell lung cancers (NSCLCs) have been performed aiming to explore the expression levels of each p63 and p73 N-terminal isoforms and their ΔN:TA expression ratio.
|
21289519 |
2011 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the current review, we will provide an overview of recent progress discussing the role of TP73 in cancer, specifically addressing its relevance to lymphomagenesis, progression, therapy resistance, and its potential as a novel therapeutic target.
|
24730526 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The transcription factor p73 synthesizes a large number of isoforms and presents high structural and functional homology with p53, a well-known tumor suppressor and a famous "Holy Grail" of anticancer targeting. p73 has attracted increasing attention mainly because (a) unlike p53, p73 is rarely mutated in cancer, (b) some p73 isoforms can inhibit all hallmarks of cancer, and (c) it has the ability to mimic oncosuppressive functions of p53, even in p53-mutated cells.
|
30635889 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LncRNA TP73 antisense RNA 1T (TP73-AS1) plays an important role in human malignancies.
|
30643007 |
2019 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition p73 and p63 are, in contrast to p53, rarely mutated in human cancer.
|
10618710 |
1999 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings implicate p73 in regulation of cancer metabolism and suggest that TAp73 influences glutamine and serine metabolism, affecting GSH synthesis and determining cancer pathogenesis.
|
24186203 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also discuss the significance of p73 and p63 for cancer therapy and outline novel approaches in development of therapeutic drugs that specifically target the p53 family.
|
18801697 |
2009 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p73 gene is located on 1p36.2-3, a region that is frequently deleted in human cancer.
|
10416592 |
1999 |